European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product ...
Efficacy data from sub-group analysis for Apealea show significant advantage with regards to progression free survival in patients with first relapse. Oasmia Pharmaceutical AB (NASDAQ: OASM) AB today announce that the European Medicines Agency (EMA) has …